Sarah B. Whittle

Sarah B. Whittle

Auto-generated profile, based on publicly available information

Sarah B. Whittle

Texas Children's Cancer and Hematology Centers, Texas Children's Hospital, Houston, Texas

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 July 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SWSarah B. Whittle
Sarah B. Whittle
MHM. John Hicks
M. John Hicks
ARAngshumoy Roy
Angshumoy Roy
SVSanjeev A. Vasudevan
Sanjeev A. Vasudevan
KRKiranmye Reddy
Kiranmye Reddy
RVRajkumar Venkatramani
Rajkumar Venkatramani

16 August 2016 in Journal of Cellular Biochemistry
Verified
Journal Article
Closed access
PDF file
PZPeter Zage
Peter Zage
SWSarah B. Whittle
Sarah B. Whittle
JSJason Shohet
Jason Shohet

4 July 2017 in Pediatric Hematology and Oncology
Verified
Journal Article
Closed access
SWSarah B. Whittle
Sarah B. Whittle
KWKaitlin C. Williamson
Kaitlin C. Williamson
HRHeidi V. Russell
Heidi V. Russell
High-risk neuroblastoma is an aggressive childhood cancer with poor outcomes. Treatment begins with an induction phase comprised of intense multi-agent chemotherapy with the goal of maximally reducing tumor bulk. Given the high intensity of induction chemotherapy, neutropenic fever and infectious complications are common; however, the actual incidence is difficult to determine from clinical trial reports. We performed a retrospective review of infection-related complications in 76 children treated for high-risk neuroblastoma at Texas Children's Hospital. Medical records were reviewed for demographics, febrile neutropenia (FN) episodes, presence, and type of bacterial and fungal infections, and potential risk factors for infection. Fifty-seven percent of patients developed one or more serious bacterial or fungal infections during induction chemotherapy. Additionally, over 75% of patients had at least one admission for FN. Risk factors for developing any infection included female sex, MYCN amplification, and having Medicaid. Patients with external central venous catheters and those requiring parenteral nutrition had higher rates of bacteremia or fungemia. Each cycle, 50% were readmitted for either FN or infection. The overall burden of infectious complications was high, with 70% having two or more unplanned admissions for infection or FN. The incidence of febrile neutropenia and serious bacterial and fungal infections during induction chemotherapy for high-risk neuroblastoma is high. Most patients had at least two additional hospitalizations for infectious complications. Risk factors including female sex, MYCN amplification, payer status, and type of central access were associated with higher rates of infection in this cohort. Abbreviations: CLABSI Central line associated blood stream infection; CTCAE Common Terminology Criteria for Adverse Events; FN Febrile neutropenia; ANC Absolute neutrophil count; TPN Total parenteral nutrition.

4 May 2022 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Closed access
SWSarah B. Whittle
Sarah B. Whittle
SFStephanie Fetzko
Stephanie Fetzko
ARAngshumoy Roy
Angshumoy Roy
RVRajkumar Venkatramani
Rajkumar Venkatramani
Sarcomas with BCOR alteration are a heterogenous group characterized by changes including internal tandem duplications (ITDs) and recurring fusions with CCNB3, ZC3H7B, and other rare partners. With widespread genomic testing, these alterations are now associated with histologies such as Ewing-like sarcoma (BCOR::CCNB3), high-grade endometrial stromal sarcoma (ZC3H7B::BCOR), and clear cell sarcoma of kidney (BCOR-ITD). BCOR altered sarcomas of soft tissues and organs were identified through PubMed using keywords “Sarcoma (AND) BCOR” from 2005 through October 2021. Summary statistics and outcome data were calculated using STATA v12.1. Forty-one publications described 190 patients with BCOR altered soft tissue or organ sarcomas. BCOR-ITD was most common, followed by BCOR::CCNB3, ZC3H7B::BCOR. BCOR-ITD tumors occurred mainly in infants, BCOR::CCNB3 commonly occurred in adolescent young adults, and ZC3H7B::BCOR only in adults. The most common site for BCOR::CCNB3 fused tumors was extremity, BCOR-ITD kidney and ZC3H7B::BCOR uterus. Metastasis was rare in patients with BCOR::CCNB3. While most underwent resection and chemotherapy, few received radiation. Median follow-up of survivors was 24 months. Five year overall survival for patients with BCOR::CCNB3 fusions was 68% (95% confidence interval [CI]: 46%-83%). Patients with BCOR-ITD and ZC3H7B::BCOR had worse prognoses with 5 years overall survival of 35% (95% CI: 15%-56%) and 41% (95% CI: 11%-71%), respectively, demonstrating need for collaborative efforts identifying optimal treatments to improve outcomes.

16 April 2019 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SWSarah B. Whittle
Sarah B. Whittle
MLMichelle A. Lopez
Michelle A. Lopez
HRHeidi V. Russell
Heidi V. Russell

16 June 2021 in Pediatric Blood & Cancer
Verified
Journal Article
Closed access
PDF file
SWSarah B. Whittle
Sarah B. Whittle
KOKatharine Offer
Katharine Offer
RRRyan D. Roberts
Ryan D. Roberts
ALAmy LeBlanc
Amy LeBlanc
CLCheryl London
Cheryl London
PHPooja Hingorani
Pooja Hingorani